Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract and have gained considerable research and treatment interest, especially in the last two decades. GISTs are driven by mutations commonly found in the KIT gene and less commonly in the platelet-derived growth factor receptor alpha gene, BRAF gene and succinate dehydrogenase gene. GISTs behave in a spectrum of malignant potential, and both the tumor size and mitotic index are the most commonly used prognostic criteria. Whilst surgical resection can offer the best cure, targeted therapy in the form of tyrosine kinase inhibitors (TKIs) has revolutionized the management options. As the first-line TKI, imatinib offers treatment for advanced and metastatic GISTs, adjuvant therapy in high-risk GISTs and as a neoadjuvant agent to downsize large tumors prior to resection. The emergence of drug resistance has altered some treatment options, including prolonging the first-line TKI from 1 to 3 years, increasing the dose of TKI or switching to second-line TKI. Other newer TKIs, such as sunitinib and regorafenib, may offer some treatment options for imatinib-resistant GISTs. New molecular targeted therapies are being evaluated, such as inhibitors of BRAF, heat shock protein 90, glutamine and mitogenactivated protein kinase signaling, as well as inhibitors of apoptosis proteins antagonist and even immunotherapy. This editorial review summarizes the recent research trials and potential treatment targets that may influence our future patient-specific management of GISTs. The current guidelines in GIST management from Europe, North America and Asia are highlighted.
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) account for less than 1% of all gastrointestinal tumors, and the prevalence of histological type comes after adenocarcinoma and lymphoma. GISTs are, however, the most common mesenchymal tumors of the gastro intestinal tract [1] . Historically, GISTs were classified as leiomyomas or leiomyosarcomas due to smooth muscle features observed under light microscopy.
GISTs were first termed in 1983 by Mazur and Clark [2] , who discovered that the majority of gastric wall tumors were not derived from smooth muscle and nerve sheath origin using immunohistochemistry. GISTs are believed to arise from the interstitial cells of Cajal or their precursors and are heterogeneous histologically, showing spindle cells (70%), epitheloid cells (20%) and mixed cells (10%) [3] . The histogenesis of GISTs has since gained considerable research and treatment interest.
A systematic review of populationbased cohort studies on GISTs by Søreide et al [4] showed that incidence ranges from low 0.43 per 100000 per year in Shanxi Province, China to high 1.62.2 per 100000 per year in South Korea. The cohort of 13550 patients from 19 countries gave the reported age ranging from 10100 years, with median age in the 60 s; both male and female populations had about equal distribution. The anatomical locations of GISTs are frequently the stomach (55.6%) and small bowel (31.8%), and are less commonly found in the colon and rectum (6%), other various locations (5.5%) and esophagus (0.7%) [4] . Primary GISTs are commonly symptomatic (in about 80% cases), presenting with gastrointestinal bleeding or obstructive symptoms and abdominal pain. Incidental asymptomatic GISTs are discovered in less than 20% of cases during other gastrointestinal endoscopy or imaging investigations.
The diagnostic tests for GISTs may include gastro intestinal endoscopy (Figure 1 Open or laparoscopic complete surgical R0 resection of GISTs (Figure 6 ) represent the only potentially curative treatment, but certain high risk features of the resected GISTs give rise to recurrence of the disease. DeMatteo et al [5] reviewed 200 patients with GISTs treated and followedup at a single institution and found that 46% had primary disease, 47% had metastasis and 7% had isolated local recurrence. Eighty patients with primary disease who underwent complete resection had 5year survival rate of 54%. Survival was predicted by tumor size, but not by microscopic resection margin. However, tumor recurrence was noted to occur at the original primary tumor site, peritoneum and liver. These data predated the use of tyrosine kinase inhibitors (TKIs). In later years, the treatment options for residual or progressive liver metastases of GISTs included hepatic artery embolization, radio frequency ablation or liver resection [68] . Historical assessment of the malignant potential in GISTs were based on the criteria of tumor size, mitotic count, proliferating cell nuclear antigen and proliferation index, which allowed classification into lowand highrisk subgroups [9] . Subsequently, different risk stratification systems for GISTs were proposed, such as the National Institutes of Health (NIH) consensus criteria (Fletcher's criteria based on size and mitotic count) and the Armed Forces Institute of Pathology criteria (Mittinen's criteria based on size, mitotic count and tumor site) and the 8 th edition of the International Union Against Cancer utilizing TNM classification in addition to a grade category based on mitotic count [1012] . According to the NIH criteria for primary GISTs, the distribution of risk is categorized as very low risk (15%), low risk (30%), intermediate risk (22%) and high risk (33%) [10] . Table 1 shows the commonly used criteria for assessing malignant risk of GISTs.
Other factors associated with a higher malignant risk of GISTs are the presence of necrosis, high cellularity, invasion to serosa or adjacent structure and rich vascularity. In addition, factors associated with a higher risk of recurrence of GISTs are now recognized to be incomplete R1 or R2 resection margin, tumor rupture and spillage during surgery.
GENETIC MUTATIONS IN GISTs
The landmark article by Hirota et al [13] discovered that GISTs express the protooncogene KIT and that this KIT gene mutation provides growth stimulation of GISTs. cKIT, also known as CD117, is a protein and a type of a receptor tyrosine kinase found on the surface of a variety of cell types; it is also a type of tumor marker. The binding of stem cell factor to the extracellular domain of cKIT induces receptor dimerization and activation of downstream signaling pathways responsible for progrowth signals within the cells. identified and localized to exon 15 V600E [15] . Mutations of the SDH gene are found to be localized to subunit B, C and D [17] . Table 2 summarizes the frequency of different genetic mutations in GISTs.
TKIs AND BIOLOGICAL THERAPY IN

GISTs
Whilst complete surgical resection of GISTs can offer the best cure, targeted therapy in the form of TKIs has altered our management options. A landmark case report by Joensuu et al [18] described the effect of a TKI called STI571 in a patient with a metastatic GIST, for which the evaluation of MRI and 18 FDGPET scans showed a very dramatic reduction of the GIST.
STI571 was the first TKI, also called imatinib, approved by the United States Food and Drug Admini stration (FDA) in 2002 for the treatment of unresected or metastatic GISTs. In 2008, imatinib was approved for adjuvant use in highrisk resected GISTs patients to prevent recurrence [19] . In 2012, the FDA granted the extension of standard 1 year imatinib therapy to 3 years, due to increase in overall patient survival [20, 21] . An important study demonstrated that imatinib when used as a neoadjuvant therapy decreased the tumor volume and was associated with improved complete surgical resection in the locally advanced primary GISTs [22] . In a trial examining the relationship between kinase genotype and treatment outcome for 428 patients treated with either 400 mg or 800 mg daily doses of imatinib confirmed the favorable impact of KIT exon 11 genotype, when compared with KIT exon 9 and wild Another landmark article by Heinrich et al [14] later discovered GISTs lacking KIT expression have muta tions related to plateletderived growth factor receptor alpha (PDGFRA). Overall, KIT or PDGFRA mutations are found in 85% and 5% of GISTs respectively. Agaram et al [15] later discovered BRAF mutation in imatinibnaïve and imatinibresistant GISTs. This BRAF mutation in GISTs is quite rare, accounting < 1% of cases [16] . It is noted that these KIT, PDGFRA and BRAF gene mutations are mutually exclusive.
"Wildtype" GISTs were previously referred to GISTs lacking any mutation in KIT and PDGFRA. This "wildtype" terminology should be avoided now that new mutations have been discovered in BRAF genes and in genes encoding the protein succinate dehydrogenase (SDH). About 12%15% of adult GISTs and 90% of pediatric GISTs lacking KIT, PDGFRA or BRAF mutations are classified into SDH-deficient and nonSDHdeficient groups. The SDHdeficient group includes Carney triad (GISTs, pulmonary chondroma and extraadrenal paraganglioma) and CarneyStratakis syndrome (GISTs and paraganglioma) [17] . The vast majority of KIT mutations are localized in exon 11 (juxtamembrane domain; about 70%), exon 9 (extracellular dimerization motif; 10%15%), exon 13 (tyrosine kinase 1 domain; 1%3%), and exon 17 (tyrosine kinase 2 domain and activation loop; 1%3%) [18] . Secondary KIT mutations in exons 13, 14, 17 and 18 are commonly identified in postimatinib biopsy specimens, after the patients have developed the acquired resistance. The mutations of PDGFRA are noted to be localized in exon 12, 14 and 18, and more specifically as 18 D842V. The mutation of BRAF is 
KIT mutation (about 85%)
PDGFRA mutation (about 5%) BRAF mutation (< 1%) SDH mutation (12%-15% adult, 90% pediatric GIST) type genotype for patients with advanced GISTs [23] . The American College of Surgeons Oncology Group led a trial studying the longterm outcome of patients categorized as high risk of recurrence who underwent complete gross GISTs resection followed by adjuvant imatinib at 400 mg/d for 1 year. After a median followup of 7.7 years, the 1, 3 and 5year overall survival rates were 99%, 97% and 83% respectively, which compared favorably with a historical 5year overall survival rate of 35%. The 1, 3 and 5year recurrencefree survival rates were 96%, 60% and 40% respectively. On univariate analysis, age and mitotic rate were associated with overall survival. On multivariate analysis, the recurrencefree survival rate was lower with increasing tumor size, small bowel site, KIT exon 9 mutation, high mitotic rate, and older age [24] . TKIs other than imatinib are considered as second generation TKIs, and include sunitinib, regorafenib, sorafenib, nilotinib, dasatinib and pazopanib. Table 3 summarizes the implication of different mutations in GISTs and their response to TKI therapy.
Sunitinib was approved by the FDA for the treatment of imatinibresistant GISTs in 2006 and is considered as secondline TKI [25] . Heinrich et al [26] discovered clinical activity of sunitinib after imatinib failure is significantly influenced by both primary and secondary mutations in the predominant pathogenic kinases that implicate the optimum treatment of patients with GISTs. Regorafenib was approved by the FDA in 2013 to treat advanced GISTs that cannot be surgically removed and are resistant to other TKIs, and it is considered as thirdline TKI [27] . The longterm followup results of the multicenter phase Ⅱ trial of regorafenib in patients with metastatic or unresectable GISTs after failure of imatinib and sunitinib showed benefit in patients with primary KIT exon 11 mutations and SDH deficient GISTs [28] . The use of other TKIs, apart from imatinib, sunitinib and regorafenib, is still being evaluated and remains debated. In a Korean clinical trial in 2012, sorafenib was shown to maintain disease control in onethird of the patients with metastatic GISTs who had otherwise failed with two or more TKIs [29] .
In a phase Ⅰ study of singleagent nilotinib or in combination with imatinib in patients with imatinib resistant GISTs showed some partial clinical response but required phase Ⅱ doses for further evaluation [30] .
In a phase Ⅱ study of imatinibresistant GISTs treated with dasatinib, there was a significant activity by objective response rate but it did not meet the predefined 6 mo progressionfree survival rate of 30% [31] . There is an American phase Ⅱ clinical trial of dasatinib in advanced sarcoma including GISTs patients and a European phase Ⅱ trial of dasatinib as first-line therapy in GISTs patients [32, 33] . Both trials have stopped recruiting participants and the conclusion of the study is expected in the future.
In a phase Ⅱ French trial, Mir et al [34] showed that pazopanib plus best supportive care improves pro gressionfree survival compared with best supportive care alone in patients with advanced GISTs resistant to imatinib and sunitinib. This trial provides reference outcome data for future studies of targeted inhibitors in the thirdline setting for this group of patients.
Other TKIs identified in clinical trials include masitinib (AB1010), crenolanib (CP868,596), AZD2171, vatalanib (PTK787), OSI930, TKI258 and DCC2618 (Table 4) . A biologics inhibitor of KIT and PDGFRA called olaratumab (IMC3G3) was trialed (NCT01316263) but the development was put on hold and the stage 2 of this study was not completed. [23] Sunitinib [25] Regorafenib [28] KIT 
Imatinib
CURRENT RESEARCH IN GISTs
The emergence of TKIresistant GISTs has led to further research in understanding of this treatment failure and the alternative signaling mechanism con ferring GIST survival. The research to find new drugs, particularly targeted therapy, is being evaluated. Agaram et al [15] found that BRAF mutations appear to be associated with a higher malignant risk and resistance to TKI compared to KIT and PDGFRA mutations. Kinase inhibitors targeting BRAF may be considered as an effective therapeutic option in this GISTs subset. Falchook et al [35] published the first report on BRAF inhibitor, dabrafenib (GSK2118436), which showed prolonged anti-tumor activity in V600E BRAFmutated GIST patients. There is presently no trial in GISTs looking at BRAF inhibitors.
In a phase Ⅱ trial study of heat shock protein (HSP)90 inhibitor, BIIB021, given to patients with GISTs refractory to imatinib and sunitinib, promising response was shown [36] . This result encourages future development of HSP90 inhibitors in TKIresistant GISTs. A next phase study evaluating BIIB021 in GISTs is therefore warranted.
Testing for germline mutations in SDH is presently recommended for patients with GISTs lacking mutations in KIT, PDGFRA and BRAF [37] . There is an ongoing phase Ⅱ trial of vandetanib in children and adults with "wildtype" GISTs but it is currently not recruiting participants and the estimated study conclusion will be available in 2023 [38] . Another study currently recruiting participants is the glutamine inhibitor CB839 trial in solid tumors including SDH-deficient GISTs [39] . Ran et al [40] recently reported the combined in hibition of mitogen activated kinase (MAPK) and KIT signaling synergistically destabilizes the transcription factor called ETV1 and suppresses GIST growth. The combination of MAPK inhibitors and TKIs to target ETV1 may provide an effective therapeutic strategy in GISTs clinical management. There is currently a trial recruiting participants to study MEK162 in combination with imatinib in patients with untreated advanced GISTs [41] . In another emerging target category, Falkenhorst et al [42] discovered inhibitor of apoptosis proteins (IAPs) such as XIAP and survivin are commonly dysregulated in GISTs. Future study to assess the combination of imatinib with an IAP antagonist such as YM155 to enhance the proapoptotic activity in GISTs is therefore needed.
There was a clinical trial study looking at the role of immunotherapy by combining pegylatedinterferon α2b with imatinib for treatment of stage Ⅲ/Ⅳ GISTs that yielded highly promising clinical outcomes. The trial was terminated early in 2012 in preparation for a larger future trial [43] . Table 4 summarizes the potential treatment targets in GISTs under clinical trials. The trials' information was obtained from https://clinicaltrials.gov/ ct2/home online. TKI of KIT and PDGFRA Masitinib (AB1010) NCT00998751 (U) [57] Crenolanib (CP-868,596) NCT02847429 (R), NCT01243346 (C) [58] AZD2171 NCT00385203 (C) [59] Vatalanib (PTK787)
CURRENT TREATMENT GUIDELINES FOR
GISTs
NCT02571036 (R) Biologic inhibitors of KIT and PDGFRA
NCT01294202 (C) Inhibitors of pathways downstream of KIT and PDGFRA RAS/RAF/MEK/ERK/MAPK inhibitors: MEK162 NCT01991379 AKT inhibitors: perifosine NCT00455559 (C) [60] mTOR inhibitors: everolimus (RAD001) NCT01275222 (C), NCT00510354 (C), NCT02071862 (R) mTOR inhibitors: temsirolimus (Torisel) NCT00700258 (R) Cell cycle inhibitors Alvocidib (Flavopiridol) NCT00098579 (C) Insulin-like growth factor pathway inhibitors OSI-906 NCT01560260 (C) [61] [4450] . Most recently, the Asian Consensus Guidelines (2016) for the Diagnosis and Management of GISTs was published to promote optimal care for Asian populations [51] . The NCCN task force report update on GISTs management is quite comprehensive and detailed, and covers over 41 pages. It described the epidemiology from the Surveillance, Epidemiology and End Results data from the National Cancer Institute, the clinical presentation, the pathology and differential diagnosis using immunohistochemistry and gene expression profiling, the recommendations for diagnosing GISTs, the significance of KIT and PDGFRA mutation status, the recommendations for mutational analysis, the management of adult vs pediatric patients with GISTs, the principles of surgery for GISTs, the need for multidisciplinary management for primary, recurrent or metastatic GISTs and the imaging of GISTs [44] . The ESMO clinical practice guidelines on GISTs describes the incidence of GISTs in Europe, the strategy to diagnose GISTs, the stage classification and risk assessment (does not recommend TNM classification), the staging procedure using CT, MRI and FDGPET scan, the treatment planning involving multidisciplinary team for localized and metastatic disease, the response evaluation and optimal followup for different risk categories [45] . In the Asian consensus guidelines for diagnosis and management of GISTs, some points were highlighted. Firstly, it recommends the minimal 3year treatment with imatinib before and after surgery for highrisk GISTs. Secondly, it recommends early evaluation of tumor response after 1 mo of neoadjuvant imatinib treatment, when genotyping is not feasible for primary gastric GISTs. Thirdly, it suggested a prospective study on the feasibility and efficacy of highdose imatinib therapy in Asian patients. Lastly, it recommends imatinib rechallenge instead of discontinuing TKI treatment if thirdline regorafenib is not available or failed [51] . In summary of these published treatment guide lines, the general consensus is complete surgical resection of GISTs as the first step when possible. Surgery is potentially curative for primary GISTs that have not metastasized and the probability of recurrence will depend on the malignant potential risk stratification criteria.
GIST cases that are initially inoperable may be given neoadjuvant therapy with the firstline TKI imatinib to improve resectability. Following complete removal of primary GISTs, patients with a higher risk of tumor recurrence may consider adjuvant therapy with firstline TKI. Patients with metastatic GIST disease, even if removed, will benefit from TKI to maintain disease control.
For patients with imatinibresistant GISTs, sunitinib is a secondline drug treatment whilst regorafenib is the thirdline drug for imatinib or sunitinibresistant GISTs. Some drugs approved for other conditions may be prescribed offlabel for GISTs at a physician's discretion but with a caveat, and clinicians are advised to follow the local guidelines. New molecular targeted drugs are being tested in many clinical trials and some are still under development. An algorithm for the management of GISTs based on the summary of current guidelines is included (Figure 7 ).
PROGNOSIS
Data from pooled analysis of 2560 patients diagnosed with operable GISTs who were not given adjuvant therapy gave the estimated 15year recurrencefree survival after surgery at 59.9% [52] . Whilst in a trial previously alluded to with resected GISTs deemed high risk were subsequently treated with imatinib showed the 5year overall survival rate of 83% [24] . In a different followup study to assess the longterm survival of 695 patients with metastatic GISTs who were treated with imatinib, the estimated 10year overall survival is 23% [53] . There was an interesting Dutch study which high lighted that severe fatigue occurred in 30% of patients with GISTs and in 33% of patients with GISTs who took TKIs. The disabling fatigue was associated with psychological distress and physical function [54] . In another survey study, the long term functional outcomes of laparoscopic resection of gastric GISTs were investigated by utilizing the Gastrointestinal Quality of Life Index (GIQLI). Most patients reported no change in symptoms and the GIQLI scores were within the normal range, with minimal effect on long term quality of life [55] .
FUTURE GIST TREATMENT TRENDS
About 5 years ago, Dematteo [56] proposed a concept of personalized therapy for GISTs. With accumulating research data in biology, such as genetic mutations and adjuvant or neoadjuvant therapy with systemic drugs, it is considered true that personalized assessment and therapy may appear to be the future trend for GIST management.
Complete surgical resection of GISTs is the gold standard of primary treatment when possible, with or without the adjunct of molecular targeted drug therapy. Through the understanding of the mutations of GISTs and addressing treatment resistance with TKIs, new treatment ideas such as combination trials of TKI plus other drugs, TKI plus surgery in specified sequences, newer line TKIs, inhibitors of BRAF, HSP inhibitors, inhibitors of downstream pathways such as MAPK, IAP inhibitors and immunotherapy may play 
